this result will also entitle the company to large amounts of non dilutive funding in the period ahead for this cardiovascular category. Aptoll recieved 6 million on their infarct results in non dilutive funding
Ann: Supplementary NYR-BI03 Study Confirm Strong Cardioprotection, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
0.070(25.0%) |
Mkt cap ! $73.82M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 35.0¢ | 28.5¢ | $423.1K | 1.316M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 20970 | 2 |
View Market Depth
| Last trade - 16.17pm 21/07/2025 (20 minute delay) ? |
| NYR (ASX) Chart |